THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA. INITIAL PUBLIC ISSUE OF EQUITY SHARES ON THE EMERGE PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED (NSE EMERGE) IN TERMS OF THE CHAPTER IX OF THE SEBI (ICDR) REGULATIONS, 2018 AS AMENDED FROM TIME TO TIME.

(Please Scan this QR to view the Prospectus)

ANIL BAGHI HOSPITAL
ESTABLISHED 1985 NABH ACCREDITED SUPER-SPECIALITY

ABH HEALTHCARE LIMITED

Corporate Identity Number: U85300PB2021PLC052886

Our Company was originally incorporated as a private limited company in the name and style of "ABH Healthcare Private Limited" under the provisions of the Companies Act, 2013 vide certificate of incorporation dated March 2, 2021 issued by the Deputy Registrar of Companies, Central Registration Centre. Further, in accordance with the main objects, our Company acquired the sole proprietorship concern of Dr. Kamal Baghi, our Promoter in the name "Anil Baghi Hospital" pursuant to a Business Transfer Agreement dated March 16, 2022.Subsequently, our Company was converted from a private limited company to a public limited company, pursuant to a resolution passed in the Extraordinary general meeting of our members held on October 7, 2024 and consequently, the name of our Company was changed to "ABH Healthcare Limited", and a fresh certificate of incorporation consequent upon conversion from private company to public company dated November 15, 2024 was issued by the Registrar of Companies, Chandigarh. For details of change in name and registered office of our Company, see ***"History and Certain Corporate Matters – Changes in the Registered Office"*** on page 151 of the Prospectus dated August 27, 2026.

Registered Office: Anil Baghi Road, Ferozepur, Punjab - 152002, India;| **Corporate Office:** N.A. | **Contact Person:** Mr. Rahul Sharma, Company Secretary & Compliance Officer
Mobile No.: +91 7888690018 **Email Id:** investor@anilbaghihospital.com; | **Website:** www.abhhealthcare.org | **Corporate Identity Number:** U85300PB2021PLC052886

THE PROMOTERS OF OUR COMPANY ARE: DR. KAMAL BAGHI, DR. SAURABH BAGHI AND DR. VAISHALI SAINI

THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX [INITIAL PUBLIC OFFER BY SMALL AND MEDIUM ENTERPRISES] OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 AS AMENDED ("SEBI ICDR REGULATIONS") AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON EMERGE PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE EMERGE")

OUR COMPANY HAS FILED THE PROSPECTUS DATED AUGUST 27, 2026 WITH REGISTRAR OF COMPANIES. THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON THE EMERGE PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED (NSE EMERGE) AND TRADING IS EXPECTED TO COMMENCE ON TUESDAY, SEPTEMBER 1, 2026.

BASIS OF ALLOTMENT

INITIAL PUBLIC ISSUE OF 34,29,600 EQUITY SHARES OF FACE VALUE ₹ 10/- EACH ("EQUITY SHARES") OF ABH HEALTHCARE LIMITED ("OUR COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 102 PER EQUITY SHARE (INCLUDING A SECURITIES PREMIUM OF ₹ 92 PER EQUITY SHARE) ("ISSUE PRICE"), AGGREGATING TO ₹ 3498.19 LAKHS (THE "ISSUE"), OF WHICH 1,72,800 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH FOR CASH AT A PRICE OF ₹102/- PER EQUITY SHARE INCLUDING A SECURITIES PREMIUM OF ₹ 92/- PER EQUITY SHARE AGGREGATING TO ₹ 176.26 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 32,56,800 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT AN ISSUE PRICE OF ₹ 102 PER EQUITY SHARE AGGREGATING TO ₹ 3321.94 LAKHS IS HEREINAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 30.01 % AND 28.49 % RESPECTIVELY OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

Brief description of the business of the Company: Our core focus is on providing specialised tertiary medical care in Tier 3 cities, within the state of Punjab while seeking to strike a balance between providing quality healthcare services and affordability. We operate our hospital under the "Anil Baghi Hospital" brand, honoring the Sacrifice of late Shri Anil Baghi. Located in Ferozepur, Punjab, our hospital has a capacity of 150 beds. Acquired by our Company in 2022, the hospital was established in 1985 with 30 (thirty) beds and is driven by a vision to provide affordable, accessible, and quality healthcare services, delivered with compassion. Since our acquisition, we have consistently invested in the hospital, expanding bed capacity, increasing our workforce, and introducing additional services and clinical specialties

The Issue is being made in accordance with Regulation 229(2) of the SEBI ICDR Regulations

ISSUE PRICE: ₹ 102/- PER EQUITY SHARE OF FACE VALUE OF ₹ 10/- EACH

THE ISSUE PRICE IS 10.2 TIMES THE FACE VALUE OF THE EQUITY SHARES.

RISKS TO INVESTORS

1. Our Company has been specifically formed for the purpose of acquisition of the business of M/s. Anil Baghi Hospital (sole proprietorship concern of one of our Promoters), thus we have limited operating history as a Company which may make it difficult for investors to evaluate our historical performance or future prospects
2. Our revenues are significantly dependent on our only hospital in Ferozepur, Punjab, any change in the economic or political circumstances in or around the areas of Ferozepur, could materially affect our business, financial condition and results of operations
3. If we are unable to keep pace with technological changes, new equipments and service introductions, changes in patients' needs and evolving industry standards as well as failure or malfunction of our medical or other equipments, our business and financial condition may be adversely affected.
4. We rely on certain third parties, including suppliers, and also enter into contracts with third-party payers such as insurance companies, third party administrators, corporations and government departments. Termination, non-renewal or any breach of the conditions of such contracts could have a material adverse impact on our business, financial condition and results of operations
5. We operate in a highly regulated industry, and compliance with applicable safety, health, environmental and other governmental regulations and any violations of existing regulations may adversely affect our business, results of operations and cash flows
6. Our Company has acquired M/s. Anil Baghi Hospital, the sole proprietorship concern of one of our Promoters after its incorporation vide Business Transfer Agreement dated March 16, 2022. Any future acquisition of other businesses could result in operating difficulties, integration issues and other adverse consequences due to our limited past experience in businesses.
7. We are significantly dependent on our key personnels, including our Promoters, Dr. Kamal Baghi, Dr. Saurabh Baghi, Dr. Vaishali Saini, senior management and other healthcare professionals and any loss of or our inability to attract or retain such persons could adversely affect our business, financial condition, results of operations and cash flows.
8. The object of making unidentified acquisitions may lead to significant investments in the businesses that may not be sustainable in the long run, which may result in financial losses and negatively impact the company's overall portfolio.
9. We do not own the premises where our Registered office and hospital are located. Any adverse event that requires us to vacate the said property may materially adversely affect our business operations and financial conditions.
10 We have a high debt-equity ratio and may face certain funding risks. Any further increase in borrowings may have a material adverse effect on our business, financial condition and results of operations. Further, if we do not generate sufficient amount of cash flow from operations, our liquidity and ability to service our indebtedness could be adversely affected.
11.We are exposed to legal claims and regulatory actions arising from the provision of healthcare services and may be subject to liabilities arising from claims of malpractice and medical negligence which could materially and adversely affect our reputation and prospects.
The Book Running Lead Manager associated with the issue has handled 3 Main Board till date and 25 SME Issues in the past three Fiscal, out of which 1 Main Board and 4 SME Issues closed below the Issue Price on the listing date.

(I) AVERAGE COST OF ACQUISITION:
The average cost of acquisition per Equity Share to our Promoters is mentioned as below:

Name of the Promoters	Number of Equity Shares of face value of ₹ 10 each held	Average Cost of Acquisition per Equity Share (in ₹)*
Dr. Saurabh Baghi	54,80,000	0.07
Dr. Kamal Baghi	23,99,984	10.22
Dr. Vaishali Saini	1,20,000	2.50

** As certified by our Statutory Auditor M/s G D Singhal & Associates, Chartered Accountants, pursuant to their certificate dated August 27,2026.*

(II)WEIGHTED AVERAGE COST OF ALL EQUITY SHARES TRANSACTED IN IN THE LAST THREE (3) YEARS, EIGHTEEN (18) MONTHS AND ONE (1) YEAR.
The weighted average cost of acquisition of all the Equity Shares transacted (i) in the preceding three (3) years; (ii) in the preceding eighteen (18) months; and (iii) in the preceding one (1) year from the date of the Prospectus is as follows:

Period	Weighted average cost of acquisition per Equity Share (in ₹)*	Issue Price (₹ 102) is 'X' times the weighted average cost of acquisition**	Range of acquisition price per Equity Share: lowest price – highest price (in ₹)**
Last three (3) years	Negligible	N.A.	Nil-33
Last eighteen (18) months	N.A.	N.A.	N.A.
Last one (1) year	N.A.	N.A.	N.A.

**As certified by our Statutory Auditor M/s G D Singhal & Associates, Chartered Accountants, pursuant to their certificate dated August 27, 2026*
*** The weighted average price for Equity Shares acquired during the last one year has been calculated by taking into account the amount paid by the promoter shareholder to acquire the Equity Shares and the cost of acquisition has been divided by total number of shares acquired (including bonus shares). The number of Equity Shares in the table above have been calculated on a post-split basis.*

(III)WEIGHTED AVERAGE PRICE AT WHICH THE EQUITY SHARES WERE ACQUIRED BY OUR PROMOTERS IN THE ONE YEAR PRECEDING THE DATE OF THE PROSPECTUS

The weighted average price at which the Equity Shares were acquired by our Promoters in the one year preceding the date of the Prospectus:

Name of the Promoters	Number of Equity Shares acquired in the one year preceding the date of the Prospectus**	Weighted Average Cost of Acquisition per Equity Share (in ₹)*
Dr. Kamal Baghi	Nil	N.A.
Dr. Saurabh Baghi	Nil	N.A.
Dr. Vaishali Saini	Nil	N.A.

**As certified by our Statutory Auditor M/s G D Singhal & Associates, Chartered Accountants, pursuant to their certificate dated August 27, 2026*
***The face value of Equity Shares is ₹10/- each*

(IV) The Price/ earnings Ratio based on Basic & Diluted EPS for Fiscal 2026 for the company at the Issue Price is 14.47 times
(V) Weighted Average Return on Networth for Fiscals 2026, 2025 and 2024 is 44.51%.
(VI) WEIGHTED AVERAGE COST OF ACQUISTION (WACA)
Weighted Average Cost of Acquisition Compared to Floor Price and Cap Price is mentioned as below:

Type of transactions	WACA (in ₹)	Floor Price (in ₹ 96)	Cap Price (in ₹ 102)
a) WACA of Equity Shares based on primary issuances undertaken during the three immediately preceding years.	N.A.	N.A.	N.A.
b) WACA of Equity Shares based on secondary transactions under taken during the three immediately preceding years.	Negligible	N.A.	N.A.
There were no primary and Secondary Sales/acquisition of Equity Shares (equity securities) transactions in last 18 months and not older than 3 years from the date of the Prospectus.			

BID/ISSUE PERIOD

BID/ISSUE OPENED ON: MONDAY, AUGUST 24, 2026

BID/ISSUE CLOSED ON: THURSDAY, AUGUST 27, 2026

This Issue is being made in terms of Rule 19(2)(b) of the SCRR, through the Book Building Process and in accordance with Regulation 253(1) and (2) of the SEBI ICDR Regulations not more than 50.00% of the Issue shall be allocated on a proportionate basis to QIBs. Our Company in consultation with the BRLM has decided that "no participation by anchor investors will be considered in the IPO". Further, 5.00% of the QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and spill-over from the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. Further, not less than 15.00% of the Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders out of which(a) one third of the portion available to non-institutional investors shall be reserved for applicants with application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs (b) two third of the portion available to non-institutional investors shall be reserved for applicants with application size of more than ₹10 lakhs. Provided that the unsubscribed portion in either of the sub-categories specified in clauses (a) or (b) may be allocated to applicants in the other sub-category of non-institutional investors and not less than 35.00% of the Issue shall be available for allocation to Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All Bidders were required to participate in the Issue by mandatorily utilising the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) and UPI ID in case of UPI Bidders, if applicable, in which the corresponding Bid Amounts were blocked by the Self Certified Syndicate Banks ("SCSBs") or by the Sponsor Bank(s) under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Issue Procedure" on page 267.
For the purpose of this Issue, the Stock Exchange will be Emerge platform of National Stock Exchange of India Limited ('NSE EMERGE'). The trading is expected to commence on or before September 1, 2026*.The investors are advised to refer to the Prospectus for the full text of the Disclaimer Clause of NSE.
*Subject to the receipt of listing and trading approval from Emerge platform of National Stock Exchange of India Limited ('NSE EMERGE')

SUBSCRIPTION DETAILS

The Issue received 1,163 Applications for 48,76,800 Equity Shares (before technical rejections and after invalid bids Multiple/Duplicate/bids (UPI Mandates) not accepted by investors / blocked, bids rejected under application banked but bid not registered) resulting in 1.42 times subscription (including reserved portion of market maker portion).The Details of applications received in the Issue from Individual Investors, Non-Institutional Investors and QIBs are as under (before technical rejections):

DETAILS OF APPLICATIONS RECEIVED

Sr. No.	CATEGORY	VALID EQUITY SHARES RECEIVED IN EACH CATEGORY	NO.OF EQUITY SHARES AVAILABLE FOR ALLOCATION (AS PER PROSPECTUS	SPILL OVER / DEFICIT*	EQUITY SHARES ALLOTTED	TOTAL ALLOTMENT AMOUNT (₹)
1	Qualified Institutional Buyers	16,66,800	1,99,200	1,44,000	3,43,200	35,006,400
2	Non-Institutional Bidders (More than 2 lots & upto Rs.1,000,000/-)*	2,70,000	5,10,000	(2,40,000)	2,70,000	27,540,000
3	Non-Institutional Bidders 2 (More than Rs.1,000,000/-)*	1,45,200	10,18,800	(8,73,600)	1,45,200	1,48,10,400
4	Individual Investors	24,98,400	15,28,800	9,69,600	24,98,400	2,54,836,800
5	Market Maker	1,72,800	1,72,800	0	1,72,800	1,76,25,600
	TOTAL	**47,53,200**	**34,29,600**	**0**	**34,29,600**	**3,49,819,200**

**Issue is under subscribed in NII1 and NII2 category by 11,13,600, unsubscribed portion of NII1 & NII2 category spilled over to Individual Investor & QIB category, since sufficient balance was not available in the Individual Investor category balance share from Individual Investor category added to QIB category.*

Final Demand
A Summary of the final demand as per NSE as on Bid/Issue closing date at different Bid Prices is as under:

Sr. No.	PRICE	NO OF APPLICATION	SUM QUANTITY	% to Total	Cumulative Total	Cumulative % of Total
1	96	45	1,14,000	0.90	1,14,000	0.90
2	97	6	14,400	0.11	1,28,400	1.02
3	98	2	7,200	0.06	1,35,600	1.08
4	99	2	4,800	0.04	1,40,400	1.11
5	100	9	30,000	0.24	1,70,400	1.35
6	101	7	16,800	0.13	1,87,200	1.49
7	102	4,233	1,24,10,400	98.51	1,25,97,600	100.00
		4,304	**1,25,97,600**	**100.00**		

The Basis of Allotment was finalized in consultation with the Stock Exchange, being Emerge platform of National Stock Exchange of India Limited ('NSE EMERGE') on August 28, 2026

1. **Allotment to Individual Investors (After Technical Rejections) (including ASBA Applications) :** The Basis of Allotment to the Individual Investors, who have bid at the Issue price of ₹ 102/- per Equity Share, was finalized in consultation with NSE. This category has been subscribed to the extent of 1.00 time i.e for 24,98,400 Equity Shares . The total number of equity shares allotted in this category is 24,98,400 Equity Shares to 1,041 successful applicants

The Category-wise details of the Basis of Allotment are as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% of Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted*
1.	2,400	1,041	100.00	24,98,400	100.00	2,400	1:1	24,98,400
	Grand Total	**1,041**	**100.00**	**24,98,400**	**100.00**			**24,98,400**

****This includes a spill over of 9,69,600 equity shares added from NII1 & NII2 category***

2. **Allotment to Non- Institutional Investors (More than 2 lots and up to ₹10 lakhs) (After Technical Rejections (including ASBA application):** The Basis of Allotment to this category of Non- Institutional Investors, who have bid at the Issue price of ₹ 102/- per Equity Share, was finalized in consultation with NSE. This category has been subscribed to the extent of 0.53 times i.e 2,70,000 Equity Shares. The total number of Equity Shares allotted in this category is 2,70,000 Equity Shares to 64 successful applicants. The Category-wise details of the Basis of Allotment are as under:

Sr.No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% of Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted*
1.	3,600	41	64.06	1,47,600	54.67	3,600	1:1	1,47,600
2.	4,800	18	28.13	86,400	32.00	4,800	1:1	86,400
3.	6,000	3	4.69	18,000	6.67	6,000	1:1	18,000
4.	8,400	1	1.56	8,400	3.11	8,400	1:1	8,400
5.	9,600	1	1.56	9,600	3.56	9,600	1:1	9,600
	Grand Total	**64**	**100.00**	**2,70,000**	**100.00**			**2,70,000**

****undersubscribed portion of 2,40,000 equity shares spilled over to QIB & Individual Investor category***

3. **Allotment to Non- Institutional Investors "above ₹ 10 lakhs" (After Technical Rejections including ASBA application):** The Basis of Allotment to this category of Non-Institutional Investors, who have bid at the Issue price of ₹ 102 /- per Equity Share, was finalized in consultation with NSE. This category has been subscribed to the extent of 0.14 times i.e 1,45,200 Equity shares . The total number of Equity Shares allotted in this category is 1,45,200 Equity Shares to 9 successful applicants. The Category-wise details of the Basis of Allotment are as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% of Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted*
1.	10,800	5	55.56	54,000	37.19	10,800	1:1	54,000
2.	15,600	1	11.11	15,600	10.74	15,600	1:1	15,600
3.	24,000	2	22.22	48,000	33.06	24,000	1:1	48,000
4.	27,600	1	11.11	27,600	19.01	27,600	1:1	27,600
	Grand Total	**9**	**100.00**	**1,45,200**	**100.00**			**1,45,200**

****undersubscribed portion of 8,73,600 equity shares spilled over to QIB & Individual Investor category***

4. **Allotment to Market Maker:** The Basis of Allotment to the Market Maker, who have bid at the Issue price of ₹ 102/- per Equity Share, was finalized in consultation with NSE. The category has been subscribed to the extent of 1.00 time i.e for 1,72,800 Equity Shares . The total number of Equity Shares allotted in this category is 1,72,800 Equity Shares to 1 successful applicant. The details of the Allotment are as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% of Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted
1.	1,72,800	1	100.00	1,72,800	100.00	1,72,800	1:1	1,72,800
	Grand Total	**1**	**100.00**	**1,72,800**	**100.00**			**1,72,800**

5. **ALLOTMENT TO QUALIFIED INSTITUTIONAL BUYERS (QIBS) (AFTER TECHNICAL REJECTION):** The Basis of Allotment to QIBs, who have bid at the Issue price of ₹ 102/- per Equity Share, has been done on a proportionate basis in consultation with NSE. This category has been subscribed to the extent of 4.86 times of QIB Portion i.e 16,66,800 Equity shares. The total number of Equity Shares allotted in this category is 3,43,200 Equity Shares, which were allotted to 2 Successful Applicants . The category- wise details of the Basis of Allotment are as under:

Sr. No.	Category	FI's/BANK	MF'S	IC'S	NBFC'S	AIF	FPC/FII	Others	TOTAL
1.	**QIB**	-	-	-	-	-	3,43,200	-	**3,43,200**

****this includes a spill over of 1,44,000 added from NII1 & NII2 category***

6. **ALLOTMENT TO ANCHOR INVESTORS :** Nil as our Company in consultation with the BRLM had decided that "no participation by anchor investors will be considered in the IPO".

The Board of Directors of the Company at its meeting held on August 28, 2026 has (i) taken on record, the Basis of Allotment of Equity Shares approved by NSE Emerge, the Stock Exchange, (ii) allotted the Equity Shares to the successful applicants and (iii) authorized the corporate action for the issue of Equity Shares to successful applicants. The Allotment Advice cum Refund Intimation have been dispatched to the email IDs and the addresses of the applicants, as the case may be, as registered with the depositories or as filled in the bid forms application forms on or before August 29th, 2026. In case the same is not received within 10 days, Investors may contact the Registrar to the Issue at the address given below.

Continued on Next Page...

Continued from Previous Page...

The instructions to Self-Certified Syndicate Banks for (i) unblocking of the funds and (ii) transfer to the public issue account, have been or will be sent and emailed, as the case may be, on or before August 31st, 2026. The Equity Shares allotted to successful applicants have been or will be credited to their respective beneficiary accounts on or before August 31st, 2026, subject to validation of the account details with the depositories. The Company has filed the listing application with NSE on August 31st, 2026 and is in the process of obtaining the listing and trading approval from NSE. Trading of the Equity Shares is expected to commence on September 1, 2026

Note: All capitalised terms used and not specifically defined herein shall have the same meaning as Ascribed to them in the Prospectus dated August 27, 2026 ("Prospectus") filed with the Registrar of Companies, Chandigarh.

INVESTORS, PLEASE NOTE

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, **BIGSHARE SERVICES PRIVATE LIMITED at** www.bigshareonline.com . All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the first/ sole bidder, serial number of the application form, date of submission of the bid cum application form, number of shares applied, DP ID, Client ID, PAN, address of the bidder, name and address of the designated intermediary / SCSB branch where the bid cum application was submitted by the bidder and payment details with the copy of the acknowledgment slip issued by the designated intermediary / SCSB branch, at the address given below.

BIGSHARE SERVICES PRIVATE LIMITED
Address: S6-2, 6th Floor, Pinnacle Business Park, Mahakali Caves Road, next to Ahura Centre, Andheri East, Mumbai- 400093, Maharashtra, India
Telephone: +91 22 62638200
E-mail: ipo@bigshareonline.com
Contact Person: Mr. Sagar Pathare
Website: www.bigshareonline.com
SEBI Registration No.: INR000001385
Investor Grievance E-Mail: investor@bigshareonline.com

On the behalf of Board of Directors
For ABH Healthcare Limited
Sd/-
Rahul Sharma
Company Secretary and Compliance Officer

Date: August 31, 2026
Place: Ferozepur

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF ABH HEALTHCARE LIMITED.

Disclaimer: **ABH Healthcare Limited** has filed the Prospectus dated August 27,2026 with Registrar of Companies, Chandigarh and thereafter with NSE and SEBI. The Prospectus is available on the website of SEBI at www.sebi.gov.in, the website of Fedex Securities Private Limited, BRLM at www.fedsec.in ,website of the NSE Limited at www.nseindia.com and website of Issuer Company at www.abhhealthcare.org. For details, investors should refer to and rely on the Prospectus including the section titled ***"Risk Factors"*** beginning on page 27 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in 'offshore transactions' in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.